FORMULATION AND EVALUATION OF SAXAGLIPTIN-LOADED TRANSFEROSOMAL ORAL THIN FILMS FOR ENHANCED PERMEABILITY

The present research work on the formulation, development, and evaluation of Fulvestrant Solid Lipid Nanoparticles (SLNs) was successfully completed. Different formulations were prepared and evaluated to develop an effective sustained-release nanoparticulate drug delivery system for Fulvestrant. The prepared formulations exhibited satisfactory physicochemical characteristics with good stability and compatibility between the drug and excipients. All the pre-compression parameters, including angle of repose, bulk density, tapped density, Carr’s index, and Hausner’s ratio, were found to be within the acceptable IP limits, indicating good flow and compressibility properties of the powder blend. Similarly, all post-compression parameters such as hardness, friability, weight variation, thickness, drug content, and in-vitro drug release were also found to comply with IP standards. Among all the formulations, F4 formulation was considered as the optimized formulation based on its superior evaluation parameters and drug release profile. The F4 formulation showed a maximum cumulative drug release of 98.41% over a period of 48 hours when compared to other formulations, indicating an effective sustained-release behaviour and better formulation performance. Thus, the developed Fulvestrant Solid Lipid Nanoparticle formulation demonstrated enhanced drug release characteristics and may improve the bioavailability and therapeutic efficacy of Fulvestrant. The study concludes that SLNs are a promising and efficient carrier system for the controlled delivery of Fulvestrant and can be further explored for advanced pharmaceutical applications. Keywords: Fulvestrant Solid Lipid Nanoparticle